作者: David R. Spriggs , Carlo Tondini
DOI: 10.1007/BF00944181
关键词: Hypersensitivity reaction 、 Leukopenia 、 Perfusion 、 Anesthesia 、 Gastroenterology 、 Chemotherapy 、 Toxicity 、 Medicine 、 Cardiotoxicity 、 Mucositis 、 Internal medicine 、 Neurotoxicity
摘要: A Phase I trial of Taxol administered as a 120 h infusion once every 3 weeks was conducted in 20 patients with advanced cancer. The initial dose 5 mg/m2/d (25 mg/m2 total dose) and received 10 mg/m2/d, 25 30 36 mg/m2/d. Forty-four courses taxol were all evaluable for toxicity. Grade 4 leukopenia the limiting toxicity observed 50% treated Significant mucositis also at All resolved within three treatment no cumulative observed. No neurotoxicity or cardiotoxicity episodes hypersensitivity reaction noted. We conclude that is an appropriate phase II testing this schedule.